@article{TLCR34453,
author = {Wenhua Liang and Kaican Cai and Chun Chen and Haiquan Chen and Wentao Fang and Junke Fu and Xiangning Fu and Shugeng Gao and Jian Hu and Yunchao Huang and Ganning Jiang and Wenjie Jiao and Shanqing Li and Gaofeng Li and Hecheng Li and Hui Li and Xiaofei Li and Naixin Liang and Deruo Liu and Hongxu Liu and Jun Liu and Lunxu Liu and Yang Liu and Qingquan Luo and Haitao Ma and Weimin Mao and Zhongmin Peng and Guibin Qiao and Guoguang Shao and Lijie Tan and Qunyou Tan and Qun Wang and Changli Wang and Qingchen Wu and Shidong Xu and Songtao Xu and Lin Xu and Yue Yang and Fenglei Yu and Baijiang Zhang and Lanjun Zhang and Bo Zhao and Xiuyi Zhi and Alessandro Brunelli and René Horsleben Petersen and Chia-Chuan Liu and Biagio Ricciuti and Giulio Metro and Alessandro Tuzi and Matteo B. Suter and Matthew Evison and Nobuhiko Seki and Shinji Sasada and Takhiro Izumo and William Chi-Shing Cho and Jianxing He and written on behalf of National Clinical Research Center for Respiratory Disease and Thoracic Surgery Branch of China International Exchange and Promotion Association for Medical and Healthcare and Chinese Alliance Against Lung Cancer and AME Thoracic Surgery Collaborative Group},
title = {Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition)},
journal = {Translational Lung Cancer Research},
volume = {8},
number = {6},
year = {2019},
keywords = {},
abstract = {Non-small cell lung cancer (NSCLC) is the most common and fatal tumor worldwide, with 2.1 million new cases and 1.77 million deaths per year (1). With the wider application of examination approaches and the improvement of health awareness, higher proportions of surgically resectable early and mid-stage lung cancers have been detected. In overall, only 50% of patients have been cured after radical resection. In other cases, however, NSCLC is highly active and recurrence and/or metastasis can easily occur after surgery. In these patients, systemic therapy as a postoperative adjuvant therapy is required to eliminate or reduce residual micro-lesions to lower the risk of recurrence; meanwhile, the patients should be closely monitored to detect early recurrence. EGFR mutation is a major mutation type in lung cancer, and is seen in about 40% of lung cancer cases in Asia (2). Compared with wild types and other mutation types, EGFR-mutant NSCLC has its unique biological properties and drug susceptibilities, and thus requires specific diagnosis and treatment strategies. This expert consensus aims to review the current evidence and provide recommendations on key issues.},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/34453}
}